NEW YORK – Roche subsidiary Foundation Medicine announced Friday it has acquired precision oncology firm Lexent Bio to help expand its liquid biopsy platforms and advance cancer care.
Financial and other details of the deal were not disclosed.
NEW YORK – Roche subsidiary Foundation Medicine announced Friday it has acquired precision oncology firm Lexent Bio to help expand its liquid biopsy platforms and advance cancer care.
Financial and other details of the deal were not disclosed.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.